Pacira Pharmaceuticals Inc (PCRX) Expected to Post Earnings of $0.24 Per Share

Wall Street analysts expect that Pacira Pharmaceuticals Inc (NASDAQ:PCRX) will post earnings of $0.24 per share for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have provided estimates for Pacira Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.35 and the lowest estimate coming in at $0.04. Pacira Pharmaceuticals posted earnings per share of $0.38 in the same quarter last year, which would indicate a negative year-over-year growth rate of 36.8%. The business is scheduled to issue its next quarterly earnings report on Wednesday, February 27th.

According to Zacks, analysts expect that Pacira Pharmaceuticals will report full-year earnings of $0.82 per share for the current financial year, with EPS estimates ranging from $0.60 to $0.92. For the next financial year, analysts forecast that the company will post earnings of $1.28 per share, with EPS estimates ranging from ($0.30) to $1.87. Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Pacira Pharmaceuticals.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, November 1st. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.40. Pacira Pharmaceuticals had a positive return on equity of 2.74% and a negative net margin of 1.30%. The business had revenue of $83.45 million during the quarter, compared to analyst estimates of $79.87 million. During the same period in the prior year, the company posted $0.11 EPS. The business’s revenue for the quarter was up 23.9% compared to the same quarter last year.

A number of brokerages recently issued reports on PCRX. Barclays increased their price objective on Pacira Pharmaceuticals from $40.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, August 6th. Wedbush set a $85.00 price objective on Pacira Pharmaceuticals and gave the stock an “outperform” rating in a report on Monday, August 6th. Mizuho reissued a “hold” rating and issued a $43.00 price objective on shares of Pacira Pharmaceuticals in a report on Thursday, November 1st. ValuEngine lowered Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 20th. Finally, Stifel Nicolaus began coverage on Pacira Pharmaceuticals in a report on Thursday, September 13th. They issued a “sell” rating and a $41.00 price objective for the company. Two analysts have rated the stock with a sell rating, ten have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $53.76.

In related news, Director Gary W. Pace acquired 4,500 shares of the business’s stock in a transaction dated Monday, November 19th. The stock was bought at an average price of $46.18 per share, for a total transaction of $207,810.00. Following the transaction, the director now owns 32,819 shares of the company’s stock, valued at $1,515,581.42. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Lauren Bullaro Riker sold 1,000 shares of the stock in a transaction on Monday, September 24th. The shares were sold at an average price of $50.70, for a total value of $50,700.00. Following the sale, the vice president now owns 11,474 shares of the company’s stock, valued at approximately $581,731.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 151,221 shares of company stock valued at $7,403,146. 5.90% of the stock is currently owned by corporate insiders.

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Pacira Pharmaceuticals by 7.2% during the 3rd quarter. Vanguard Group Inc. now owns 3,641,417 shares of the company’s stock valued at $178,976,000 after acquiring an additional 243,213 shares during the last quarter. Partner Fund Management L.P. lifted its position in shares of Pacira Pharmaceuticals by 82.5% during the 2nd quarter. Partner Fund Management L.P. now owns 3,110,213 shares of the company’s stock valued at $99,682,000 after acquiring an additional 1,405,605 shares during the last quarter. Macquarie Group Ltd. lifted its position in shares of Pacira Pharmaceuticals by 5.7% during the 3rd quarter. Macquarie Group Ltd. now owns 2,453,888 shares of the company’s stock valued at $120,609,000 after acquiring an additional 132,763 shares during the last quarter. Schroder Investment Management Group lifted its position in shares of Pacira Pharmaceuticals by 2.4% during the 2nd quarter. Schroder Investment Management Group now owns 1,255,030 shares of the company’s stock valued at $38,969,000 after acquiring an additional 29,223 shares during the last quarter. Finally, Stephens Investment Management Group LLC lifted its position in shares of Pacira Pharmaceuticals by 13.9% during the 2nd quarter. Stephens Investment Management Group LLC now owns 1,198,271 shares of the company’s stock valued at $37,206,000 after acquiring an additional 146,319 shares during the last quarter. Institutional investors own 97.84% of the company’s stock.

Shares of PCRX stock opened at $48.62 on Friday. Pacira Pharmaceuticals has a 12-month low of $26.95 and a 12-month high of $55.00. The company has a market capitalization of $1.99 billion, a P/E ratio of -83.83, a price-to-earnings-growth ratio of 82.62 and a beta of 1.65. The company has a debt-to-equity ratio of 0.95, a current ratio of 8.66 and a quick ratio of 7.83.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Featured Article: Asset Allocation, Balancing Your Investments

Get a free copy of the Zacks research report on Pacira Pharmaceuticals (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit